News Publications
In May 2025, Lumedica Vision made a notable appearance at the ARVO Annual Meeting held in Salt Lake City, Utah, showcasing its latest innovation— the OQ EyeScope 2.0—for the very first time to the vision research community. At Booth 1737, attendees experienced a live demonstration of this Research Use Only (RUO) portable OCT device, designed for faster acquisition and enhanced imaging performance, marking a significant upgrade from previous iterations. According to Interim CEO Dr. Adam Wax, the debut underscored the company’s mission to democratize high-resolution retinal imaging by making sophisticated OCT technology more accessible and affordable for labs and clinical researchers alike.
2025 - Attended ARVO in Salt Lake City, UT. Showed the OQ EyeScope 2.0 /RUO
In March 2025, Lumedica Vision’s continued innovation in affordable imaging was featured in Translational Vision Science & Technology with the publication “High-Performance, Low-Cost Optical Coherence Tomography System Using a Jetson Orin Nano for Real-Time Control and Image Processing.” Co-authored by Dr. Adam Wax and collaborators, the study introduced a compact OCT system powered by NVIDIA’s Jetson Orin Nano, enabling real-time GPU-accelerated processing. The system achieved a fivefold increase in speed without sacrificing image quality, all while reducing device volume by 67% and computing cost by 22%. These improvements preserve affordability while dramatically enhancing performance—advancing the case for widespread, point-of-care OCT deployment in clinical and low-resource settings.
2025 - Research Paper Publication: High-Performance, Low-Cost OCT Using a Jetson Orin Nano
Lumedica Vision was proud to attend the ARVO 2024 Annual Meeting, where we joined leading vision researchers and clinicians from around the world to share our latest advancements in affordable OCT imaging. Our team had the opportunity to showcase the power of low-cost, high-performance optical coherence tomography technology, and engage in meaningful discussions about expanding access to diagnostic tools in both research and clinical settings. We're grateful for the chance to connect with innovators in the field and look forward to continuing collaborations that drive forward the future of eye care.
2024 - Attended ARVO in Seattle, WA. Showed the OQ EyeScope 1.0 /RUO, along with featuring Lumedica’s new animal scans
2023 - Attended ARVO in New Orleans, LA. Showed the OQ EyeScope 1.0 /RUO for the first time
In April 2023, Lumedica Vision made its debut at the ARVO Annual Meeting in New Orleans, exhibiting at Booth 1022. For the first time publicly, they showcased the OQ EyeScope 1.0 as a Research Use Only (RUO) device—marking a critical milestone in bringing their portable OCT imaging system into the hands of vision researchers. This unveiling provided researchers and clinicians the earliest opportunity to interact with the OQ EyeScope in a live setting, enabling hands-on demonstrations that highlighted its potential to deliver affordable, high-resolution retinal imaging for broader clinical and research applications.
In September 2022, Lumedica Vision’s portable OCT technology was featured in the peer-reviewed publication “Enhancing Portable OCT Image Quality via GANs for AI-based Eye Disease Detection”, presented at the International Workshop on Distributed, Collaborative, and Federated Learning and published by Springer Nature. Co-authored by Dr. Adam Wax, CEO of Lumedica Vision, the study explored how generative adversarial networks (GANs) can enhance imaging quality from low-cost, portable OCT (p-OCT) systems to support AI-driven diagnostics for eye diseases such as glaucoma, AMD, and diabetic retinopathy. The research validated the potential of Lumedica’s compact imaging devices to serve underserved populations and low-resource settings, addressing key barriers to access in ophthalmology. The study marked an important intersection of affordable hardware and advanced machine learning, reinforcing Lumedica’s commitment to innovation in equitable eye care delivery.
2022 - Research Paper Publication: Enhancing portable OCT image quality via GANs for AI-based eye disease detection
2019 - Pepperdine, Graziadio Business School Most Fundable Companies List Award
In November 2019, Lumedica Vision received a prestigious honor from Pepperdine University’s Graziadio Business School, being named the third Most Fundable Company in the annual “Most Fundable Companies” survey. The rigorous program evaluated over 3,500 early-stage U.S. startups, scrutinizing factors such as business model viability, market opportunity, leadership team strength, advisory board quality, and competitive edge. Lumedica’s recognition—announced at a high-profile gala showcase—highlighted their OCT-based medical device innovation and underscored investor confidence in their mission to democratize access to retinal disease screening . Their CEO, Dr. Adam Wax, expressed gratitude for the feedback and national visibility, noting that this accolade would accelerate their progress in making eye care diagnostic technologies more accessible globally.
2019 - Nextcorps Luminate, Luminate Innovators Award
In June 2019, Lumedica Vision was honored as one of the Luminate NY Innovators during NextCorps' high-profile accelerator competition. Competing in Round II’s Demo Day, Lumedica earned the third-place prize, which included $250,000 in follow-on funding—making it the only company from outside New York to receive financial recognition that year. This award recognized the strength of their patented OQ EyeScope portable OCT device and underscored the company’s compelling business plan and technological innovation. Supported by Luminate’s six-month program of mentorship in manufacturing, commercial strategy, and investor readiness, Lumedica leveraged the accolade to expand its impact in ophthalmic screening and advance its mission to democratize retinal disease detection.
2019- Nextcorps Luminate Honorable Achievement
In June 2019, Lumedica Vision—led by Interim CEO Dr. Adam Wax, a co‑founder and Professor of Biomedical Engineering at Duke University—participated in Luminate NY’s third cohort, securing the third-place award and $250,000 in funding. The recognition made them the only company outside New York to receive a prize that year. Over the rigorous six‑month accelerator, the team honed their portable OCT technology and commercial strategy, benefiting from NextCorps’ mentorship in manufacturing and investor readiness. Dr. Wax noted the profound impact of the program: “We’re honored, excited and so grateful to have been invited to participate in this program […] this award helps us move closer to achieving our mission of detecting and preventing blindness around the world”
In May 2019, Lumedica Vision’s affordable OCT technology was featured in the peer-reviewed journal Translational Vision Science & Technology through the publication “First Clinical Application of Low-Cost OCT.” Co-authored by Dr. Adam Wax and collaborators, the study detailed the design and clinical deployment of a fully stand-alone, low-cost spectral-domain OCT system. Tested on 120 eyes, the device demonstrated imaging performance comparable to a commercial Heidelberg OCT, with only a 5.6% reduction in contrast-to-noise ratio. The results validated the system’s ability to support diagnostic retinal imaging at a fraction of the cost, underscoring its potential to expand access to high-quality eye care in low-resource settings.
2019 - Research Paper Publication: First Clinical Application of Low-Cost OCT
2018 - Luminate NY Lightning Award
In November 2018, Lumedica Vision was selected as one of the ten finalists in the second cohort of Luminate NY and participated in the prestigious Lightning Awards, which took place at the Dryden Theatre in Rochester’s George Eastman House. As part of the cohort, each finalist received an initial $100,000 investment and began the six-month accelerator program in January 2019, based out of the Sibley Building. Lumedica’s inclusion underscored its promise in photonics-driven ophthalmic devices; the company’s portable OQ EyeScope—designed for early-stage retinal disease detection—was a key innovation that helped earn their spot among global and U.S. finalists